New Haven’s Rallybio reports that its drug candidate RLYB212 showed strong results in a proof-of-concept study as a treatment for a rare immune disorder in fetuses and newborns.
The company reported earlier this month that clinical proof-of-concept has been achieved in a Phase 1b study for the drug candidate, an anti-HPA-1a monoclonal antibody used in the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT).